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Abstract 18 
Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 19 
fracture, poor bone healing and other skeletal complications. In addition, some anti-diabetic 20 
therapies for T2DM can have notable detrimental skeletal effects. Thus an appropriate 21 
therapeutic strategy for T2DM should not only be effective in re-establishing good glycaemic 22 
control but also in minimising skeletal complications. There is increasing evidence that 23 
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), now greatly prescribed for the 24 
treatment of T2DM, have beneficial skeletal effects although the underlying mechanisms 25 
are not completely understood. This review provides an overview of the direct and indirect 26 
effects of GLP-1RAs on bone physiology, focusing on bone quality and novel mechanisms of 27 
action on the vasculature and hormonal regulation. The overall experimental studies 28 
indicate significant positive skeletal effects of GLP-1RAs on bone quality and strength 29 
although their mechanisms of actions may differ according to various GLP-1RAs and clinical 30 
studies supporting their bone protective effects are still lacking. The possibility that GLP-31 
1RAs could improve blood supply to bone, which is essential for skeletal health, is of major 32 
interest and suggests that GLP-1 anti-diabetic therapy could benefit the rising number of 33 
elderly T2DM patients with osteoporosis and high fracture risk.  34 
 35 
Lay Abstract 36 
Bone weakening is an important complication in individuals with type 2 diabetes (T2DM). 37 
This review summarises the effects on skeletal health of drugs that are similar to the 38 
hormone Glucagon-like peptide-1 (GLP-1), which are now used increasingly for the 39 
treatment of T2DM and could lead to a stronger skeleton.  40 
  41 
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1 Introduction 42 
Diabetes mellitus (DM) is a chronic disease that progresses worldwide at alarming rates. For 43 
instance, in 2013, it has been estimated that DM affected 382 million individuals 44 
(Federation, 2013). Projections for 2035 indicate a global burden of 55% to reach up to 592 45 
million individuals (Federation, 2013). Associated complications are commonly cardio-46 
vascular events, nephropathy, retinopathy, neuropathy and bone fragility that dampen the 47 
quality of life of affected individuals.  48 
Type 2 diabetes mellitus (T2DM) is by far the most common form of DM and is characterised 49 
by chronic hyperglycaemia and hyperinsulinaemia mostly caused by insulin resistance (IR) in 50 
peripheral tissues such as the liver and muscle. The aetiology of bone fragility in T2DM is 51 
unclear. Indeed, bone mineral density is normal or slightly elevated in T2DM despite an 52 
increase risk of femoral neck fracture, suggesting alterations of bone "quality" rather than 53 
bone mass (Vestergaard et al., 2005, Schwartz et al., 2011, Napoli et al., 2016). Bone quality 54 
is an umbrella term that regroups factors such as bone microarchitectures, tissue material 55 
properties and bone toughness (Chappard et al., 2011). Another important contributor for 56 
bone fracture is represented by an increased risk in falls in this population (Schwartz et al., 57 
2002, Schwartz et al., 2008). At the cellular and molecular levels, T2DM is characterised by a 58 
reduction in bone turnover suggesting modifications of bone cell behaviours (Vestergaard, 59 
2007). Furthermore, low testosterone and vitamin D levels, and high plasma sclerostin, are 60 
common features observed in T2DM patients (Sellmeyer et al., 2016).  61 
Current treatment options of T2DM rely on lifestyle intervention and oral or injectable 62 
drugs, when needed, to reach an HbA1C level of 7% or less. Among the most prescribed 63 
drugs, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted 64 
attention as Glp-1r knockout animals and GLP-1 supplemented animals exhibited 65 
modifications of bone strength and quality as described below.  66 
Endogenously, GLP-1 is produced by post-translational processing of the glucagon gene in 67 
enteroendocrine cells, mainly L-cells (Habib et al., 2012). Two forms of GLP-1 are produced 68 
in the intestine, GLP-17-36NH2 and GLP-17-37 although the major circulating form is GLP-17-36NH2 69 
(Orskov et al., 1994). L-cells are an open type endocrine cells highly polarised with secretory 70 
granules at their basolateral pole ready to be released in the capillary network running 71 
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through the lamina propria. This secretion is regulated by intraluminal contents, neural 72 
stimuli and hormones (Baggio and Drucker, 2007). Beyond its endocrine mode of action, 73 
GLP-1 has also been suspected to act via the autonomous nervous system and hypothalamic 74 
and brainstem nuclei (Holst and Deacon, 2005).  75 
To act, GLP-1 engages its receptor; the GLP-1r that is coded by the human GLP1R gene 76 
comprising 13 exons that span approximately 13.8kb (Yamada et al., 1995) and localised on 77 
chromosome 6p21 (Gremlich et al., 1995). The GLP-1r is expressed in the endocrine 78 
pancreas, gastro-intestinal tract, lung, heart, kidney and several regions of the brain (Baggio 79 
and Drucker, 2007). Recent evidences also suggest that GLP-1 can bind in specific 80 
circumstances to the glucagon receptor (Weston et al., 2015). The principal physiological 81 
role of GLP-1 is to potentiate glucose-dependent insulin secretion (McIntosh et al., 2010). 82 
Extrapancreatic actions of GLP-1 results in reduction of food intake through the CNS, 83 
inhibition of gastric emptying, positive actions on the cardiovascular system and a role in 84 
energy expenditure (McIntosh et al., 2010).  85 
GLP-1RAs are GLP-1 with extended half-life to be more resistant to degradation by the 86 
dipeptidyl peptidase-4 (DPP-4) enzyme. Several molecules listed in Table 1 have been 87 
developed by the pharmaceutical industry and now been approved for the treatment of 88 
T2DM. The aim of the present review is to provide the reader with a comprehensive analysis 89 
of the effects of GLP-1RAs on bone physiology with special focuses on the mode of action 90 
including effects on bone quality, blood flow to bone, and on the hormonal regulation of 91 
bone metabolism.   92 
 93 
2 Pathogenesis of bone fragility in diabetes 94 
As mentioned in the introduction section, the aetiology of diabetes seems linked to bone 95 
quality rather than bone quantity. As such it is important to understand what alterations of 96 
bone tissue are observed in T2DM individuals.  97 
 98 
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2.1 Alterations in bone microarchitecture and bone material properties 99 
Often, the assessment of bone microarchitecture and material properties require the use of 100 
bone biopsy as a source of bone tissue for experimental investigation. However, such 101 
biopsies are not available and microarchitecture and material properties have been 102 
investigated in humans by high resolution peripheral quantitative computed tomography 103 
(HR-pQCT) and bone microindentation. In term of bone microarchitecture, most studies 104 
tend to indicate a preserved trabecular bone microarchitecture but an increase in cortical 105 
bone porosity in diabetic individuals with or without fracture (Burghardt et al., 2010, Farr et 106 
al., 2014, Patsch et al., 2013). A limitation of HR-pQCT is that it can only be performed at 107 
peripheral skeletal sites and may not reflect the full bone phenotype.  108 
In terms of bone material properties, the use of the OsteoProbe bone microindentation 109 
device showed that postmenopausal women with T2DM had significantly lower bone 110 
material strength index (BMSi) as compared to age- and sex-matched postmenopausal 111 
women without diabetes, suggesting altered bone material properties (Farr et al., 2014).  112 
 113 
2.2 Advanced glycation endproducts 114 
Prolonged hyperglycaemia leads to the formation of advanced glycation endproducts (AGEs) 115 
in the bone matrix that can impair its mechanical properties and the behaviour of bone 116 
cells. The most studied AGEs in humans is pentosidine because of its easiness to be 117 
measured in clinical samples such as blood or urine. As such, serum and urine pentosidine 118 
levels have been correlated with clinical fractures in T2DM patients (Schwartz et al., 2009, 119 
Yamamoto et al., 2008). However, further work is required to determine the extent to which 120 
circulating levels of AGEs reflect those in human bone tissue.   121 
 122 
2.3 Bone turnover markers and circulating sclerostin levels 123 
Multiple studies in humans have found that serum markers of bone formation and 124 
resorption are reduced in diabetic individuals vs. non-diabetic controls (Dobnig et al., 2006, 125 
Gerdhem et al., 2005, Krakauer et al., 1995, Shu et al., 2012). In contrast, circulating levels 126 
of sclerostin have reported to be higher in diabetic individuals (Garcia-Martin et al., 2012, 127 
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Gaudio et al., 2012, Gennari et al., 2012) and with regards to sclerostin’s potent inhibitory 128 
action on bone formation, this may exacerbate the low bone formation phenotype in those 129 
patients. As such, long-standing low bone turnover observed in diabetes may result in a 130 
defective microdamage repair and increased bone microcrack accumulation that can further 131 
contribute to the observed fracture risk. Enzymatic cross-linking of type I collagen by lysyl 132 
oxidase is reduced in diabetes (Khosravi et al., 2014, Saito et al., 2006). As circulating 133 
markers of bone resorption are based on cross-linked fragments of type I collagen, it is 134 
possible that bone resorption is underestimated in diabetes.  135 
 136 
3 Skeletal effects of GLP-1RAs: direct and/or indirect mechanisms of action 137 
3.1 Clinical studies  138 
Clinical data on the skeletal effects of GLP-1RAs are scarce. Bone turnover markers and bone 139 
mineral density have been assessed in T2DM patients treated with exenatide and liraglutide. 140 
However, all these studies reported no effects of GLP-1RA treatment on circulating bone 141 
markers or bone mineral density (Li et al., 2015, Bunck et al., 2011, Gilbert et al., 2016). 142 
Interestingly, the effects of liraglutide administration on bone turnover markers have been 143 
reported not in diabetic but in the obese population for the weight-loss action of liraglutide. 144 
In that study, bone formation was improved as indicated by higher values for N-terminal 145 
propeptide of type 1 procollagen reported in the liraglutide arm, but no effects on bone 146 
resorption were observed (Iepsen et al., 2015). 147 
Two meta-analyses have also been performed on the use of GLP-1RAs and the possible 148 
effects of these medications on fracture risk. They showed divergent effects on bone 149 
fractures and differences among GLP-1RAs. It was demonstrated that liraglutide significantly 150 
reduced the risk of bone fractures whereas exenatide treatment was associated with an 151 
elevated risk of incident bone fractures (Su et al., 2015). The other meta-analysis however 152 
found neutral effect of both liraglutide and exenatide as compared with other anti-diabetic 153 
medications (Mabilleau et al., 2014). Interestingly, Driessen and colleagues (Driessen et al., 154 
2015b, Driessen et al., 2015a) investigated in the British and Danish populations the 155 
incidence of bone fracture in GLP-1RA takers as compared with non-takers. No significant 156 
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difference was observed and they suggested that the effect of both GLP-1RA-type was 157 
neutral in the human diabetic population.  158 
However, interpretation of the above clinical studies and meta-analyses/observational 159 
studies should be done carefully as they have some limitations:  160 
• Bone fractures were not the principal end-points and as such are often disclosed as a 161 
serious adverse event, although this represents only a fraction of all fractures 162 
• There is a lack of information on bone status (bone mineral density, 163 
microarchitecture, bone quality) and calcium and phosphorus metabolism at 164 
baseline and at the end of studies that could highlight the possible action of GLP-165 
1RAs on bone strength 166 
• The duration of studies may not be long enough to allow for improvement in bone 167 
quality independently of bone turnover markers  168 
• The incidence of GLP-1RAs on falls, and hence a possible mechanism of action to 169 
reduce fracture, is very scarce. 170 
Furthermore, as discussed below, a reduction in bone fracture has been evidenced with 171 
DPP-4 inhibitors (Monami et al., 2011). However, several differences exist between DPP-4 172 
inhibitors and GLP-1RAs. First, GLP-1RAs induce a modest weight loss whilst DPP-4 inhibitors 173 
are neutral on that aspect (Amori et al., 2007, Inzucchi et al., 2012).  After the age of 50, 174 
weight loss is associated with an increased risk of fracture in overweight and obese 175 
individuals (Jensen et al., 1994, Langlois et al., 2001). Secondly, the most common 176 
treatment-emergent adverse events with GLP-1RAs are nausea, vomiting and diarrhoea and 177 
it is plausible that they result in malabsorption of mineral and nutrients, negatively affecting 178 
bone physiology.  179 
In clinical trials, GLP-1RAs have been effective in reducing HbA1c level and hence chronic 180 
hyperglycaemia. Data on AGEs and pentosidine in response to GLP-1RAs on the other hand 181 
are limited. Tanaka et al, (Tanaka et al., 2015a) demonstrated that despite evident action of 182 
liraglutide in reducing circulating glucose in Japanese overweight/obese patients with 183 
T2DM, the effects of such molecule on circulating pentosidine were null.  184 
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 185 
3.2 Effect of DPP-4 inhibitors on the skeleton 186 
The other class of pharmacotherapeutic agents that uses the incretin system are DPP-4 187 
inhibitors which inhibit the principal enzyme responsible for the degradation of endogenous 188 
GLP-1. By decreasing clearance of GLP-1, concentrations of active GLP-1 are increased by 2- 189 
to 3-fold, resulting in a lowering of fasting and postprandial glucose concentrations.  190 
Data regarding the effects of DPP-4 inhibitors on human skeletal health are quite scarce. A 191 
meta-analysis carried out on 28 trials suggests a reduced fracture risk with DPP-4 inhibitors,  192 
dependent on the treatment duration (Monami et al., 2011). However, not all studies are 193 
showing a positive effect of DPP-4 inhibitors on fracture risk, BMD and bone turnover 194 
(Monami et al., 2011, Driessen et al., 2014). Recent preclinical studies showed protective 195 
effect of DPP-4 inhibitors on the skeleton of diabetic rats (Glorie et al., 2014, Eom et al., 196 
2016) while others have shown no effect (Gallagher et al., 2014). In vitro studies have also 197 
indicated neutral effects of DPP-4 inhibitors on bone formation (Gallagher et al., 2014). 198 
Therefore, DPP4 inhibitors could have a possible protective effect mediated by an increase 199 
of the circulating concentrations of GLP-1 or no adverse effect. Overall, although the 200 
interest in this new anti-diabetic treatment effect on bone is high, unfortunately to date 201 
data on DPP-4 inhibitors do not allow the stating of recommendations.  202 
 203 
3.3 Experimental studies  204 
The first understanding of GLP-1 actions in skeletal physiology arises from Glp1-r KO mouse. 205 
At 10 weeks of age, these mice exhibited a small reduction in bone mass associated with an 206 
increased number of osteoclasts and eroded surfaces (Yamada et al., 2008). On the other 207 
hand, the mineral apposition and bone formation rates appeared unaffected by GLP-1r 208 
inactivation (Yamada et al., 2008). Similarly, observations in the same KO model at 16 weeks 209 
of age and in the double incretin receptor knockout model at 26 weeks of age corroborated 210 
these findings (Mabilleau, 2017, Mieczkowska et al., 2015). Taken together these results 211 
suggested a control of bone resorption (osteoclast differentiation and/or action) by the GLP-212 
1r. According to the literature, this effect on resorption seems to be indirect through a 213 
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reduction in calcitonin gene expression in GLP-1r-deficient animals (Yamada et al., 2008) but 214 
further evidences are warranted.  215 
While it is well established that GLP-1RAs increase bone mass in rodents (see paragraph 4), 216 
previous investigations of their effects on bone turnover are conflicting. It has been 217 
reported that 3 μg/kg/day and 4.2 μg/kg/day exenatide induced bone formation by 218 
osteoblast activation in old ovariectomised (OVX) rats (Ma et al., 2013) and in hindlimb-219 
unloading rats (Meng et al., 2016) by promoting the osteogenic differentiation and 220 
inhibiting BMSC adipogenic differentiation. A decrease of osteoclastic surfaces was also 221 
observed (Ma et al., 2013). In contrast, we found no effect of both 10 μg/kg/day exenatide 222 
and 0.3 mg/kg/day liraglutide on bone formation and mineralisation rates in OVX mice and a 223 
slight increase of osteoclastic surfaces with the drug using bone histomorphometry (Pereira 224 
et al., 2015). The reasons for those discrepancies are unclear and may involve differences in 225 
bone turnover in mice and rats and/or in the duration of GLP-1RA treatment. Interestingly, 226 
our recent unpublished data demonstrate that GLP-1RAs increase bone formation in a 227 
T2DM mouse model but not in lean control mice, suggesting that glucose levels and/or low 228 
bone turnover may also influence the skeletal effects of GLP-1RAs. It is possible that the 229 
efficacy of GLP-1RAs on the skeleton may be improved in situations where there is a 230 
disproportionate reduction in bone formation as compared with resorption such as in 231 
T2DM. 232 
 233 
3.4 In vitro studies  234 
While several studies have reported that GLP-1RAs could have beneficial effects on the 235 
skeleton, the downstream molecular mechanisms underlying the osteogenic effect have not 236 
been identified (Bjarnason et al., 2002, Clowes et al., 2002). It is indeed unclear whether the 237 
mechanism of action of GLP-1RAs in bone is direct, through a functional GLP-1r expressed 238 
by bone cells, or indirect, via an increase in calcitonin production by the thyroid C-cell which 239 
inhibits bone resorption (Yamada et al., 2008). Furthermore, the presence and the identity 240 
of the GLP-1r in bone were controversial until recently and thus the basis for direct skeletal 241 
effects of GLP-1 has not been established. 242 
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We recently demonstrated that GLP-1 might directly affect bone cells via a GLP-1r identified 243 
in primary mouse osteoblasts isolated from calvaria and bone marrow-derived osteoclasts 244 
(Pereira et al., 2015) and this was confirmed in situ using a GLP-1r antibody (abcam). 245 
Similarly, other studies showed that mouse osteoblast-like MC3T3-E1 cells express a 246 
functional receptor for GLP-1 (Aoyama et al., 2014). In contrast, expression of the 247 
pancreatic-type GLP-1r mRNA was identified in human osteoblastic cell lines deriving from 248 
osteosarcomas, but its expression was dependent on the stage of osteoblastic development 249 
(Pacheco-Pantoja et al., 2011). However, other study failed to demonstrate the presence of 250 
GLP-1r at the mRNA level in primary murine osteoblasts or osteoclasts (Mabilleau et al., 251 
2013). Similarly, the presence of the pancreatic GLP-1r in osteocytic cells was controversial 252 
as it has been reported in some cell lines, but not all (Pereira et al., 2015, Kim et al., 2013), 253 
as well as in osteocytes in rat femurs (Kim et al., 2013). 254 
The presence of GLP-1r in bone cells in vitro and in situ implies that GLP-1RAs could have 255 
direct effects on bone cells. A study has indeed identified potential skeletal beneficial effects 256 
of 10 nM of exenatide by promoting osteoblastogenesis and restraining adipogenesis 257 
through a β-catenin pathway, during BMMSC differentiation (Meng et al., 2016). Despite 258 
increased osteoblastogenesis, no direct effect of GLP-1RAs on bone nodule mineralisation in 259 
vitro was shown with up to 100M of exenatide and 1000nM of liraglutide (Ma et al., 2013, 260 
Pereira et al., 2015). It is well established that exposure of primary osteoblast cells to high 261 
glucose levels inhibits in vitro bone nodule formation (Pereira et al., 2016, Balint et al., 262 
2001). Interestingly, despite no effect of exenatide on bone formation in normal glucose 263 
conditions, unpublished results from our group demonstrate that it can reduce the 264 
deleterious effect of glucose on bone formation in vitro, in a dose-dependent manner. This 265 
could be due to upregulated GLP-1r expression in high glucose conditions, which could in 266 
turn magnify the effect of GLP-1RAs (Aoyama et al., 2014). Regarding the effects of GLP-267 
1RAs on osteoclastogenesis in vitro, we showed that both liraglutide and exenatide 268 
increased osteoclastogenesis, while decreasing the area resorbed per osteoclast, suggesting 269 
that GLP-1RAs stimulate osteoclastic differentiation but impair their resorptive activity 270 
(Pereira et al., 2015).  271 
 272 
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3.5 GLP-1RA effects on the balance between adipogenesis and 273 
osteogenesis and adipocytes 274 
Bone marrow mesenchymal stem cells (BMMSCs) have the ability to differentiate into 275 
various cell types, including osteoblasts and adipocytes and can be targeted by anti-diabetic 276 
drugs (e.g. thiazolidinedione). Considering the reciprocal relationship between osteogenic 277 
and adipogenic differentiation, GLP1-RAs may also indirectly affect bone formation by 278 
modulating adipogenesis. Several previous in vitro studies have indeed shown that GLP-1 279 
stimulates adipose-derived stem cells (Lee et al., 2015, Cantini et al., 2015) and BMMSC (Lu 280 
et al., 2015) towards osteoblast differentiation whereas it inhibits adipocytic differentiation. 281 
Furthermore, the GLP-1R is expressed by adipocytes and GLP-1RAs down-regulates 282 
adipogenic/lipogenic genes on adipose tissue explants and cultured adipocytes while 283 
increasing lipolytic markers and expression of adiponectin (Cantini et al., 2015, El Bekay et 284 
al., 2016, Wang et al., 2017). While skeletal effects of adiponectin are multi-faceted and not 285 
always concordant, it was suggested that it may be a negative regulator of bone metabolism 286 
(Naot et al., 2017), adding to the complexity of the indirect effects of GLP-1RAs on the 287 
skeleton. Adipocyte accumulation in the bone marrow during ageing and obesity was 288 
recently shown to inhibit bone healing in mice and this was reversed by DPP-4 inhibitors, 289 
suggesting that targeting adipocytes with GLP-1RAs may also have beneficial effects on 290 
skeletal health (Ambrosi et al., 2017).  291 
 292 
3.6  Potential signalling mechanisms of GLP-1 in bone 293 
GLP-1RA binding to the classical pancreatic GLP-1r activates the main (cAMP-PKA) and 294 
alternative phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 295 
downstream signalling pathways. While it is still unclear whether GLP-1RAs’ skeletal effects 296 
are direct via a GLP-1r expressed in bone or indirect, Cantini et al, (71) suggested that in 297 
tissues other than pancreas, GLP-1 and GLP-1RAs may not exert their actions through the 298 
classical GLP-1r but via unknown alternative pathways. This was observed in 299 
cardiomyocytes, liver and muscles (Cantini et al., 2016).  300 
Similarly, GLP-1 action in bone could be mediated by a receptor different from the classical 301 
pancreatic cAMP-linked GLP-1r. In fact, Nuche-Berenguer et al, (72) identified in a mouse 302 
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osteoblastic line a receptor different from the pancreatic cAMP-linked GLP-1r. Moreover, 303 
they showed that GLP-1 binding to this different receptor induced an immediate hydrolysis 304 
of glycosylphosphatidylinositols, generating inositolphosphate glycan and activating PI3K 305 
and MAPK, without affecting cAMP/PKA classical signalling (Nuche-Berenguer et al., 2010b). 306 
Thus, the hypothesis of an indirect action of GLP-1RAs cannot be excluded. 307 
 308 
4 GLP-1RAs and bone quality 309 
Unfortunately, as neither peripheral quantitative computed tomography (pQCT) nor iliac 310 
crest bone biopsy are part of the usual care in diabetic clinical trials, human data on the 311 
effects of GLP-1RAs on all aspects of bone quality are presently missing. As such, the 312 
following summary of action of GLP-1RA is based on pre-clinical data obtained in animal 313 
models. Several animal models of either osteoporosis or T2DM have been used to assess the 314 
effects of two GLP-1RAs, exenatide and liraglutide, on bone quality and strength. However, 315 
data concerning potential bone effects of other GLP-1RAs, and especially those 316 
administered once weekly, are currently missing. Mice presenting a deletion of GLP-1r have 317 
also been generated and represented a suitable model to investigate the role of the GLP-318 
1/GLP-r pathway in bone.  319 
 320 
4.1 Effects of GLP-1RAs on bone strength  321 
Our knowledge of the effects of the GLP-1/GLP-1r pathway on bone strength has been 322 
markedly improved by the use of Glp-1r KO mice. Indeed, although these animals are not 323 
diabetic, they exhibited a significant reduction in bone strength represented by lower 324 
ultimate load and stiffness (Mabilleau et al., 2013).  Bone strength in response to the GLP-325 
1RA exenatide has also been investigated in osteoporotic animal models generated either 326 
by ovariectomy or disuse. In ovariectomy-induced osteoporosis, the use of exenatide at a 327 
concentration as low as 1 µg/kg/day for 16 weeks, led to improvement in maximum load 328 
and stiffness as well as Young’s modulus and ultimate stress, suggesting amelioration in 329 
bone microarchitecture and/or tissue material properties (Ma et al., 2013). In the rat tail 330 
suspension model, the administration of exenatide (4.2 µg/kg/day) for 4 weeks resulted in 331 
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higher value for maximum loading, stiffness, stress and Young’s modulus, suggesting here 332 
again ameliorations in bone microarchitecture and/or tissue material properties (Meng et 333 
al., 2016). However, bone strength has not been measured after treatment with liraglutide. 334 
 335 
4.2 Effects of GLP-1RAs on bone microarchitecture 336 
In Glp-1r KO animals, unpublished observations from our group, revealed that these animals 337 
presented with a reduction in cancellous bone volume associated with a lower trabeculae 338 
numbers and higher trabecular spacing. These data have been confirmed by the elegant 339 
study of Yamada et al, (Yamada et al., 2008) who reported a significant reduction in 340 
cancellous bone mineral density in the same transgenic animal model. Alterations of cortical 341 
bone in this mouse model were also evidenced with lower outer bone diameter and cortical 342 
thickness (Mabilleau et al., 2013). Exenatide and liraglutide have been used as a treatment 343 
option in pre-clinical animal models of osteoporosis. They demonstrated positive effects on 344 
trabecular bone microarchitecture in the axial and appendicular skeleton evidenced by 345 
amelioration of structural parameters in lumbar vertebra and long bones as early as 4 weeks 346 
treatment. Indeed, both liraglutide and exenatide treatments resulted in higher bone 347 
volume/total volume (BV/TV) values (24% to 148%, depending on dose and treatment 348 
duration) and higher values for trabecular number (Tb.N), thickness (Tb.Th) and reduction in 349 
separation (Tb.Sp) (Ma et al., 2013, Meng et al., 2016, Pereira et al., 2015, Sun et al., 2016, 350 
Lu et al., 2015). When comparing the effects of both GLP-1RAs, liraglutide (0.3mg/kg/day) 351 
was more potent than exenatide (10µg/kg/day) (Pereira et al., 2015). The effects of GLP-352 
1RAs on cortical microarchitecture were only observed after a minimum of 8 weeks 353 
treatment with exenatide or liraglutide, but highlighted significant increases in cortical 354 
thickness with 20µg/kg/day of exenatide or 0.6mg/kg/day of liraglutide (Lu et al., 2015, Sun 355 
et al., 2016).  356 
In opposition to what is commonly observed in humans, animal models of T2DM exhibit 357 
significant alteration of trabecular and cortical microarchitectures. The effects of GLP-1RAs 358 
in diabetic animal models have also been reported. The use of exenatide at a regimen of 359 
10µg/kg/day for 3 days in T2DM animals resulted in improvement in trabecular 360 
microarchitecture at the femur and lumbar spine (Nuche-Berenguer et al., 2011, Nuche-361 
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Berenguer et al., 2010a). The use of liraglutide was also investigated in the Goto-Kakizaki 362 
T2DM rat model at a dose of 0.4mg/kg/day for 4 weeks. This regimen led to significant 363 
improvement in trabecular and cortical bone microarchitectures in the femur and lumbar 364 
vertebra (Sun et al., 2015).    365 
The effects of liraglutide on bone microarchitecture have also been investigated in a T1DM 366 
mouse model. In this study, the administration of 0.093mg/kg/day liraglutide for 3 weeks 367 
did not demonstrate ameliorations of neither trabecular nor cortical microarchitectures 368 
(Mansur et al., 2015).  369 
 370 
4.3 Effects of GLP-1RAs on tissue material properties 371 
With respect to the improvement in bone strength and intrinsic properties (Young’s 372 
modulus, stress), that are independent of the bone architecture, one could suspect action of 373 
GLP-1RA on tissue material properties. However, very little information has been reported. 374 
Tissue material properties represent a set of parameters that describe the modification of 375 
biochemical composition or organisation of the bone matrix at the molecular and nanoscale 376 
levels (Chappard et al., 2011). This encompasses for a thorough assessment of the mineral 377 
and collagen compartment. Most of our knowledge on the action of GLP-1 on tissue 378 
material properties is based on Glp1r KO mice. Indeed, in these animals, a significant 379 
reduction in enzymatic collagen cross-linking has been evidenced and associated with 380 
alteration of bone strength at the tissue level (Mabilleau et al., 2013). However, in 381 
opposition to what has been seen with the sister incretin hormone GIP, Glp-1r deletion did 382 
not alter the mineral compartment (Mieczkowska et al., 2013).  Data regarding the potential 383 
effects of GLP-1RAs on tissue material properties in osteoporotic animals are lacking. 384 
However, an elegant study conducted by Mansur et al, (Mansur et al., 2015) investigated 385 
the effects of 0.093 mg/kg/day liraglutide over a period of 3 weeks in a T1DM mouse model. 386 
These authors reported no amelioration of enzymatic collagen cross-linking or collagen 387 
glycation but an unexpected reduction in collagen destruction (Mansur et al., 2015).   388 
 389 
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5 GLP-1RAs and blood flow to bone 390 
Diabetes leads to poor circulation and vascular diseases are the principal causes of death 391 
and disability in people with diabetes. Consequently, wound and fracture healing are 392 
delayed in diabetic patients, one of the main reasons being the impairment in 393 
vascularisation (Falanga, 2005, Loder, 1988). Particularly, diabetes was shown to induce a 394 
decrease in endothelial progenitor cells (EPC) that are important for angiogenesis and 395 
vascular repair (Fadini et al., 2005, Rigato et al., 2015). It is now well established that blood 396 
flow is crucial to bone vascular function and osteogenesis (Ramasamy et al., 2016) and that 397 
disrupted blood supply to bone is associated with reduced bone mass, osteonecrosis and 398 
impaired bone regeneration (Loder, 1988, Vogt et al., 1997, Atsumi and Kuroki, 1992). Very 399 
little work has however examined whether the bone vasculature and bone blood flow are 400 
reduced in diabetic bone and if it is possible to restore them with the use of anti-diabetic 401 
drugs. Fajardo (Fajardo, 2017) recently reviewed the literature regarding the microvascular 402 
complications in diabetic bone but evidences are still lacking to support the link between 403 
skeletal fragility in diabetes and those vascular complications.  404 
Incretin-based therapy seems very promising for the prevention of diabetic vascular 405 
complications (Mima, 2016). The potential for GLP-1RAs to enhance vascular function has 406 
been demonstrated in several studies (Nystrom et al., 2004, Zhou et al., 2015, Sufiun et al., 407 
2015, Smits et al., 2015). The improvement of vascular endothelial function restores 408 
impaired glucose tolerance by ameliorating insulin resistance in skeletal muscle (Kubota et 409 
al., 2011). Interestingly, two weeks administration of 0.5μg/kg/d exenatide was shown to 410 
accelerate diabetic wound healing by increasing angiogenesis in the wound and the number 411 
of circulating EPCs (Roan et al., 2017). Our recent, not yet published, work also 412 
demonstrates that 10µg/kg exenatide can have beneficial effects on bone vascularisation in 413 
diabetic bone by acutely increasing blood flow to bone in db/db mice. This suggests that the 414 
increased bone formation induced by exenatide treatment in diabetic mice could be 415 
attributed in part to this increased skeletal perfusion. No study has yet examined the effect 416 
of liraglutide on bone blood flow. More work is therefore needed to examine whether 417 
skeletal perfusion is linked to bone formation in diabetic bone and if GLP-1RAs could be 418 
used as treatment to increase vascularisation in diabetic patients with poor fracture healing.  419 
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 420 
6 GLP-1RAs and hormones that regulate bone metabolism 421 
A major breakthrough in the bone research field has been the finding that bone is an 422 
endocrine organ that can affect other organs via the release of hormones such as 423 
osteocalcin and sclerostin. There are increasing reports showing that GLP-1RAs can affect 424 
the release of these hormones by bone cells in vitro and in animal models but the clinical 425 
evidence is however still very scarce.  426 
 427 
6.1 Sclerostin 428 
The discovery of the importance of the Wnt/β catenin pathway for bone formation has led 429 
to extensive work examining the function of sclerostin in bone. Sclerostin is a product of the 430 
SOST gene expressed mainly by osteocytes which is secreted and acts as a potent antagonist 431 
of Wnt signalling (Bellido, 2014). Its deficiency or its pharmacological neutralisation 432 
increases bone formation, making it a potential target for treatment of bone diseases 433 
associated with bone loss, such as osteoporosis (Hamann et al., 2013, Ominsky et al., 2010). 434 
Most studies have shown that serum sclerostin levels are elevated in diabetic patients, 435 
suggesting that sclerostin could contribute to the decreased bone formation observed in 436 
diabetic patients (Garcia-Martin et al., 2012, Gaudio et al., 2012, Gennari et al., 2012). 437 
However the association between sclerostin levels and increased fracture risk in T2DM 438 
patients is not always conclusive and further studies are required to confirm the link (Yu et 439 
al., 2017). Some differences in serum sclerostin levels measurements could be explained by 440 
the fact that sclerostin could be derived from other non-skeletal sources so that serum 441 
levels may not always reflect the production in bone (Roforth et al., 2014) and also because 442 
the ELISA kits for sclerostin measurements were found to lack accuracy (Piec et al., 2016, 443 
Costa et al., 2017).  444 
To address this issue, experimental studies were conducted examining if sclerostin 445 
production by osteocytes is modified in bone of diabetic rodents or in vitro when osteocytes 446 
are cultured in high glucose levels. Although an in vitro study reported an increased 447 
production of sclerostin by osteocyte-like cell line when cultured in hyperglycemia (Pereira 448 
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et al., 2016, Tanaka et al., 2015b), our recent study shows that the impaired bone 449 
microarchitecture and cellular turnover associated with T2DM-like conditions in diabetic 450 
ZDF rats are not correlated with changes in serum sclerostin levels, bone sclerostin 451 
expression or osteocyte viability (Pereira et al., 2016). On the other hand, high fat diet in 452 
mice resulted in increased serum sclerostin and dramatic alterations of osteocyte network 453 
organisation (Mabilleau et al., 2016).  454 
Few studies have investigated if GLP-1RAs could affect sclerostin production by osteocytes. 455 
Although GLP-1r is mainly expressed by immature osteoblasts, it can be present in 456 
osteocytes where it co-localise with sclerostin (Kim et al., 2013), suggesting that GLP-1RAs 457 
may affect sclerostin production. Kim et al, (Kim et al., 2013) have indeed shown that 458 
sclerostin levels are increased in diabetic rats compared to controls and can be down-459 
regulated by exenatide treatment. More recently, they demonstrate that the DPP-4 460 
inhibitor vildagliptin lowers the increased levels of sclerostin induced by thiazolidinedione 461 
(Eom et al., 2016). Our own results showed that exenatide but not liraglutide decreased 462 
sclerostin levels in OVX mice (Pereira et al., 2015).  463 
Overall, despite some controversy, the majority of clinical and experimental studies suggest 464 
that sclerostin may play a role in the decreased bone turnover in patients with T2DM and be 465 
a potential target for GLP-1 therapy. The origin of sclerostin in serum is however still unclear 466 
and more studies are required to examine whether bone production of sclerostin is affected 467 
in T2DM patients.  468 
 469 
6.2 Osteocalcin 470 
Osteocalcin (OC) is a small protein produced in bone by osteoblasts during bone formation 471 
which has traditionally been used as a serum marker for bone formation (Ducy et al., 1996). 472 
This protein has however regained a different interest in recent years due to the 473 
demonstration that when it is in its uncarboxylated form (GluOC) which does not bind to 474 
bone, it can circulate, act as a hormone and regulate glucose metabolism (Lee et al., 2007). 475 
GluOC can stimulate the release of GLP-1 from the small intestine and therefore indirectly 476 
promote insulin secretion by the pancreatic cell (Mizokami et al., 2013).  477 
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It was suggested that incretins could contribute to whole body energy metabolism by 478 
modulating osteocalcin synthesis in osteoblasts. The effects of GLP-1RAs on osteocalcin 479 
production by osteoblasts were examined and once again the results are inconsistent. While 480 
Kim et al, (Kim et al., 2013), Nuche-Berenguer et al, (Nuche-Berenguer et al., 2010a) 481 
demonstrate an increase in serum osteocalcin levels with exenatide in T2DM and IR rats, 482 
this was not the case with liraglutide treatment (Iepsen et al., 2015, Conte et al., 2015). A 483 
recent study demonstrates that incretins inhibit thyroid hormone-stimulated osteocalcin 484 
synthesis in osteoblasts in vitro, suggesting that incretins could stimulate bone formation by 485 
reducing the osteocalcin levels (Kainuma et al., 2016), although this is not confirmed in vivo. 486 
Osteocalcin concentration significantly increases during calcification and arterial 487 
calcification is an important complication of diabetes due to the differentiation of vascular 488 
smooth muscle cells into osteoblast-like cells. Although some work demonstrates an 489 
inhibitory effect of GLP-1RAs on vascular calcifications, this is not always the case (Zhan et 490 
al., 2014, Davenport et al., 2015).   491 
 492 
6.3 Calcitonin 493 
Calcitonin is a peptide hormone produced by the thyroid parafollicular cells, commonly 494 
named "C-cells," that regulate calcium homeostasis (Warshawsky et al., 1980). Increases in 495 
serum calcium activate the release of calcitonin from the C-cells, which consecutively 496 
inhibits bone resorption by the osteoclast and calcium absorption by the intestine. It was 497 
therefore one of the first agents to be used as a treatment for osteoporosis. As mentioned 498 
previously, several animal studies suggest that GLP-1RAs can affect bone metabolism 499 
indirectly via the release of calcitonin by thyroid C cells which express the GLP-1r (Yamada et 500 
al., 2008, Lamari et al., 1996). The expression of the GLP-1r in thyroid glands has indeed 501 
been documented in rodents (Bjerre Knudsen et al., 2010), but there is an uncertainty 502 
regarding its expression in humans (Gier et al., 2012, Hegedus et al., 2011). Furthermore, 503 
basal and stimulated calcitonin did not change during 1 year of liraglutide treatment (Lunati 504 
et al., 2016). Our own work demonstrates that serum levels of calcitonin were indeed 505 
increased by exenatide treatment in ovariectomised mice (Pereira et al., 2015), although 506 
this was not shown when mice were treated with liraglutide, suggesting once again that 507 
these two GLP-1 agonists may have a different mechanism of action.  508 
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7 Differences in mechanisms of action between liraglutide and exenatide 509 
Some divergent skeletal effects of liraglutide and exenatide observed in clinical and 510 
experimental studies suggest possible different mechanisms of action. Although overall 511 
similar in action, liraglutide and exenatide treatments differ in several aspects mainly due to 512 
their differences in molecular structures. Indeed, liraglutide is an analog of human naïve 513 
GLP-1 with 97 % homology, whereas exenatide only share 50% homology with human naïve 514 
GLP-1. This molecular divergence determines the differences in pharmacokinetic profiles 515 
between liraglutide and exenatide (Jespersen et al., 2013). The half-life of liraglutide is five 516 
time longer than exenatide, therefore exenatide treatment requires twice daily injections in 517 
patients. Moreover, while exenatide is mailnly eliminated in the kidney, liraglutide is fully 518 
degraded within the body and no specific organ or enzyme is responsible for its elimination 519 
(Giorda et al., 2014). Exenatide administration also results in higher frequency of antibody 520 
formation than that of liraglutide (Buse et al., 2011). Thus, the favourable role of liraglutide 521 
on bone fractures risk and its more potent effect in vivo could be explained in part by its 522 
similar pharmacokinetic profile with human naïve GLP-1. On the other hand, exenatide 523 
possesses distinct absorption, elimination and antibody formation properties. Whether 524 
those different properties of exenatide could interact with some bone metabolism and 525 
turnover pathways needs to be clearly elucidated but this may explain the distinctive effects 526 
of these two GLP-1RAs on bone hormones production. 527 
 528 
8 Conclusion 529 
Based on several rodent studies, GLP-1 therapy emerges as one of the most promising anti-530 
diabetic therapy for treating the skeletal fragility associated with diabetes. It was shown to 531 
increase bone mass, improve trabecular and cortical architectures, enhance bone strength 532 
and tissue material properties, affecting the collagen compartment rather than the mineral 533 
one. The possible mechanisms of action of GLP-1RAs on the skeleton are illustrated in Figure 534 
1. They are however still not very clear and different GLP-1RAs may have different means of 535 
action. Among the potential ones, the stimulation of bone blood flow by GLP-1RAs seems 536 
very interesting and extremely promising in situations of osteoporotic and diabetic 537 
fractures. Clinical data are however still lacking and those establishing the relationship 538 
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between the GLP-1RA use and decrease fracture risk have been so far negative. There is 539 
therefore a need for long-term clinical studies comparing the skeletal effects of different 540 
GLP-1RAs.   541 
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Figure 1: Simplified scheme of the possible skeletal effects of GLP-1RAs 
 
GLP-1RAs exert multiple beneficial effects on the skeleton. They increase bone mass, 
improve trabecular and cortical architectures, enhance bone strength and collagen content. 
They however do not affect bone mineral density (BMD). Several potential mechanisms of 
action have been described to explain these positive effects of GLP-1RAs on bone. They 
include indirect effects of GLP-1RAs on bone turnover mediated via hormonal changes. 
GLP-1RAs were indeed shown to upregulate calcitonin production by C-cells in the thyroid 
leading to a decrease in bone resorption; alternatively they can down-regulate sclerostin 
production by osteocytes and increase bone formation. Their beneficial effects on bone 
blood flow could also contribute to a stimulation of bone formation. GLP-1RAs can also have 
direct effects on bone cells mediated by the GLP-1R expressed in primary osteoblasts, 
osteoclasts and in some osteocytes. In vitro studies suggest that GLP-1RAs may stimulate 
bone formation in condition of hyperglycemia and impair osteoclast bone resorptive activity. 
However, some divergent skeletal effects of liraglutide and exenatide were observed in 
clinical and experimental studies, suggesting that different GLP-1RAs may use various 
mechanisms of action. 
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Table 1: Summary of approved GLP-1RAs for the treatment of type 2 diabetes mellitus 
Active compound Drug name Marketed by Approved in Approved dose range 
Exenatide (or Exendin-4) Byetta Astra Zeneca AB 2006 5-10 µg twice daily 
Liraglutide Victoza Novo Nordisk A/S 2009 0.6-1.8 mg once daily 
Lixisenatide Lyxumia Sanofi Aventis Groupe 2013 10-20 µg once daily 
Exenatide (or Exendin-4) 
long acting release 
Bydureon Astra Zeneca AB 2011 2 mg once weekly 
Albiglutide 
Eperzan 
GlaxoSmithKline Trading Services 
Ltd 
2014 30-50 mg once weekly 
Dulaglutide Trulicity Eli Lilly Nederland B.V. 2014 0.75-1.5 mg once weekly 
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